posted
PHARMANETICS, INC. Parent company of Cardiovascular Diagnostics Inc. which develops, manufactures and markets rapid diagnostics to dose, manage and screen patients on drugs affecting coagulation.
05/13/2005 (16:48 ET) PHAR: Filed New Form 15-12G --------------------- PHAR Reverse Merger Info.
PHAR used to use TallkOaks Capital llc. Now, Mr. Funkouser "PHAR CEO" is the president of nContact, a private company. Guess who they just started using, TallOaks Capital.
So he is the president of a private company, and has a shell of his old public company.
Whats that mean? Yep, that is what I am thinking too!
-Spec --------------
Posted by: yplate In reply to: lifegear who wrote msg# 455 Date:8/7/2007 12:02:20 AM Post #of 475
Funkhouse is CEO/Pres of both PHAR and nContact as listed here:
The background info refers to Ablatics, but entering the Ablatics URL takes you straight to nContacts homepage.
Another name associated with both companies is Farinholt of Tall Oaks Capital Partners, LLC. Under his background info at the very bottom, "Jim has portfolio responsibility for nContact Surgical". He is/was also on the BoD of PHAR.
"We get great support from Tall Oaks. They are fully engaged and have provided good counsel, including important industry introductions - huge value-adds for a start up like nContact.”
John Funkhouser President and CEO nContact Surgical, Inc.
The purchase price for the assets to be sold pursuant to the Asset Sale Plan will be negotiated by our management at arms-length with the party or parties that desire to acquire some or all of the assets. Management will consult with such financial, legal and other advisors as they deem appropriate in these negotiations. To the extent material and as may be required by applicable law, the final purchase price and other material terms of any actual sale of assets pursuant to the Asset Sale Plan will be approved by the Board of Directors.
Within 12 months of the closing of the final sale of assets pursuant to the Asset Sale Plan, we are required to distribute to our shareholders the cash we received in the sale of the assets, if any, net of expenses incurred in connection with the sale (including the fees and expenses of our legal, financial and other advisors) and net of any amounts that may be payable to our creditors or pursuant to other contractual or other obligations. In the event any cash from the sale of assets are held in escrow or otherwise encumbered for more than 12 months following the closing of a sale, we will promptly distribute such encumbered cash as soon as it is released to us. If we receive any property other than cash in connection with the sale of assets under the Asset Sale Plan, our management will liquidate such assets for cash in a manner designed, in their discretion, to maximize the cash to be distributed to our shareholders.
IP: Logged |
Jul 23, 2006 (The Beaumont Enterprise - Knight Ridder/Tribune Business News via COMTEX) -- Drug company will create 50 local jobs
BEAUMONT -- Helena Laboratories, 1530 Lindbergh Drive, said it acquired the products and technology of PharmaNetics Inc., of Morrisville, N.C., and will move its operations to Beaumont, creating 50 jobs during the next two years.
Terms of the acquisition were not disclosed.
The new products will expand Helena's Point of Care division, which includes products for blood platelet function screening and activated clotting time-testing.
PharmaNetics developed a dry chemistry system that is used to rapidly assess blood-clot formation and dissolution for patients where they are receiving care.
The products help in treatment of angina, heart attack, stroke, and lung embolisms.
Helena, founded in 1966, will market the products under the name "Cascade POC."
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
